Bitter Leaf-Based Drugs ‘Cure’ Hepatitis, Cancer, Diabetes, TB
Nigerian researchers have in clinical trials demonstrated how poly herbal preparations made predominantly with bitter leaf (Vernonia amygdalina) provide cure for chronic form of hepatitis B and C co-infection, cancer, type 2 diabetes and tuberculosis. CHUKWUMA MUANYA writes.
NIGERIAN researchers are a step closer to a universally accepted cure for hepatitis B and C, cancer, diabetes and tuberculosis with the development of bitter leaf-based dietary supplements that have shown great promise in clinical studies. The researchers from Halamin Herbal centre, 10 George Innih Crescent, Apo District, Abuja and Department of Histopathology and Cytology, Jos University Teaching Hospital (JUTH) Jos found that poly herbal preparations with bitter leaf (Vernonia amygdalina) as the active ingredient strengthen the immune system through many cytokines and chemokines regulations.
Other constituents of poly herbal preparations include: Sesamum indicatum (sesame), bitter leaf (Vernonia amygdalina), Aloe barbadensis (popularly known as aloe vera), Saccharum officinarum (sugar cane), Allium sativum (garlic) and Amaranthus caudatus (green amaranth, inine in Ibo, tete abalaye in Yoruba).
The poly herbal preparations include: SAAAB and HAABS dietary supplement for hepatitis B and C; SAABFAT 7 for cancer; TABSAABS for tuberculosis; andDAABS-2 for type two diabetes.
The researchers led by a leading researcher in plant extracts and natural medicine and pharmacist, Dr. Ben Amodu, have shown that there is a cure for the chronic form of hepatitis B and C.
Amodu is also a member of the committee inaugurated recently by the Director General of the National Agency for Food Drug Administration and Control (NAFDAC), Dr. Paul Orhii, to champion the development of herbal medicine through scientific validation of all the cure claims.
The study titled “Clinical Activity of SAAAB and HAABS Dietary Supplement on Hepatitis C and B Markers,” was published in the January/February 2013 edition of the Journal of Pharmacy and Biological Sciences. Previous studies have shown that hepatitis B virus (HBV) and hepatitis C virus (HCV) co-infection is not uncommon as a result of similar routes of infection. Patients who are co-infected represent a unique group with diverse serologic profiles. Combined chronic hepatitis B and C leads to more severe liver disease and an increased risk of hepato-cellular carcinoma.
Until now, co-infected patients represent a treatment challenge but the researchers have discovered how the liver can be toned by some herbal extracts to an extent of making hepatitis C becomes infinitesimal and render hepatitis B markers anergic.
The researchers wrote: “With the abundant presence of tannins, phlobatannins, flavonoids, steroids, terpenoids, saponins and cardiac glycosides, which are the most important bioactive constituents of medicinal plants, the poly herbal preparation is able to reverse hepatitis B envelop antigen (HBeAg) reactive to HBeAg non reactive and makes the surface antigen of the hepatitis B virus anergic within a span of three weeks.”
They concluded: “In conclusion, this study has shown that there is a cure for the chronic form of hepatitis- HBV and HCV. The total clearance of HBeAg and HCVupon administration of SAAAB and HAABS for three weeks and one week respectively is a testimony to this fact. Therefore, since prevention still remains the key to control, efforts must be made to strengthen strategies aimed at increasing awareness and encouraging people to take seriously the issue of vaccination. It is also important for the vaccination to be made mandatory for all unvaccinated adolescents and adults.
“Furthermore to cure and improve the quality of life of people infected with the chronic form of hepatitis, the novel supplements- SAAAB and HAABS should be allowed to be dispensed in hospitals and pharmacies across the length and breathe of the country and beyond.”
The researchers in another study published in the International Journal of Pharmaceutical Science Invention found that the presence of blocking bioactive activities of SAABFAT 7 with Vernonia amygdalina as it active ingredient opens new perspectives in the treatment of cancer by means of the use of blocking or specific modulators of these radicals.
The study is titled, “Phytochemical and Biological Study on Saabfat 7 with a Focus on Vernonia Amygdalina.”
They concluded: “The affectation in the expression of these radicals and other important markers in tumoral cells of epithelial origin confirms the antitumoral effect and they reaffirm to this cocktail of natural antitumoral products as a novel and attractive alternative in the treatment of cancer.”
Cancer is considered at the moment one of the main causes of death worldwide. The current tendency in the treatment of cancer pursues to obtain a more successful treatment that do not increases alone its effectiveness but rather it diminishes its adverse effects.
According to the researchers, one of such that provides a better alternative is naturaceuticals, tagged as natural products. They are able to scavenge free radicals, induce detoxification, inhibit stress response proteins and interfere with DNA binding activities of some transcription factors. In these new therapeutic slopes the treatments are included that modify the biological answer, starting from emergent pharmacological agents able to modulate the transduction of signs inducing a selective death of the tumoral cells.
Ben Amodu and his team of researchers have also conducted an open label 12-week descriptive cross-sectional survey in a large number of patients to determine the efficacy of TABSAABS: an ethnomedicinal polyherbal formulation for the radical rapid cure for tuberculosis.
The constituents of TABSAABR include: Sesamum indicatum (sesame), bitter leaf (Vernonia amygdalina), Aloe barbadensis (popularly known as aloe vera), Saccharum officinarum (sugar cane), Allium sativum (garlic) and Amaranthus caudatus (green amaranth, inine in Ibo, tete abalaye in Yoruba).
The results of the study published in International Journal of Pharmaceutical Science Invention showed that the patients in this descriptive cross-sectional survey responded positively to the ethnomedicinal herbal formulation resulting in 100 per cent recovery level in the females and 98 per cent recovery level in the males without any toxicity or side effects observed in the patients for the eight weeks monitoring period.
The study is titled “Tabsaabr: A Novel Ethnomedicinal Polyherbal Formulation For The Radical Rapid Cure For Tuberculosis.”
The subjects in this study were 270 males (60 per cent) and 180 females (40 per cent) who were clinically diagnosed to have a mixture of Multiple-Drug Resistance tuberculosis and Extensively-Drug Resistance tuberculosis. The subjects were placed on TABSAAB, the ethnomedicinal herbal formulation for the treatment of tuberculosis for a period of 12 weeks, and the subjects were monitored for a period of eight weeks for possible relapse of signs and symptoms.
The researchers concluded: “In conclusion, this study has shown that there is a cure for Tuberculosis be it Multi Drug Resistance or Extensively Drug Resistance Tuberculosis. The total clearance of Mycobacterium tuberculosis upon administration of TABSAAB for three months is a testimony to this fact. Therefore, since prevention still remains the key to control, efforts must be made to strengthen strategies aimed at increasing awareness and encouraging people to take seriously the issue of vaccination. It is also important for the vaccination to be made mandatory for all unvaccinated adolescents and adults. Furthermore to cure and improve the quality of life of people infected with Tuberculosis, the novel supplements- TABSAAB should be allowed to be dispensed in hospitals and pharmacies across the length and breathe of the country and beyond.”
Amodu told The Guardian that four capsules of TABSAABR (480mg extracts/capsule) is taken 12 hourly for three months for the treatment of both Multiple Drug Resistant (MDR) and Extremely Drug Resistant (XDR) tuberculosis. It also can be taken two capsules 12 hourly for the treatment of malaria, waist pain, arthritis, rheumatism and as adjunct for Human Immuno-deficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS).
The result of yet another study by the researchers showed that the administration of bitter leaf extracts decreased blood glucose by 90 per cent compared to the placebo treated diabetic animals respectively.
The study published in IOSR Journal of Pharmacy and Biological Sciences is titled, “Daabs-2r: A Novel Ethnomedicinal Polyherbal Formulation For The Management Of Diabetes Mellitus.”
The researchers wrote: “This research was aimed at evaluating the efficacy ofDAABS-2, a novel ethnomedicinal polyherbal formulation on Insulin Depended Diabetes mellitus and non Insulin Dependent Diabetes mellitus by using streptozotocin (STZ)-induced diabetic laboratory animals and the result showed that the administration of 180mg/kg and 100mg/kg with the correspondingDAABS-2 extracts decreased blood glucose by 90 per cent compared to the placebo treated diabetic animals respectively.
“In summary, the present study results indicate that single i.p. injection of STZ180mg/kg and 100mg/kg with the correspondent extracts produced no diabetes of any form, while the same i.p injection of 180mg/kg and 100mg/kg with the corresponding placebo produced type 1 or insulin dependent diabetes, however, the latter failed to produce diabetes mellitus. The severity and mortality of diabetes with STZ 180mg/kg is more in comparison to 100mg/kg. The long-term complications of diabetes mellitus and the characteristics of progressive diabetes mellitus in the group with the placebo could be studied.”
- Date: February 10, 2015
- Client: Johnson Group, US